Vaxcyte, Inc. (PCVX)
$66.80-5.45%Close
BUYRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9.6B
- Beta
- 1.23
- P/E (TTM)
- -8.74
- Short % float
- 13.08%
- Days to cover
- 11.4
- SI change
- +7.2%
- 1W
- +0.15%
- 1M
- +12.19%
- vs SPY 1W
- +0.29%
- vs SPY 1M
- +9.69%
Industry peers
FMP comparable companies · ranked by market cap
- PFESELLPfizer Inc.$158.6BBULLQ 13$27.82-0.11%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.54-1.39%
- MRNABUYModerna, Inc.$78.2BRECOVERYQ 36$197.00+1.17%
- IBRXBUYImmunityBio, Inc.$10.4BRECOVERYQ 8$9.91-3.16%
- VIRBUYVir Biotechnology, Inc.$1.9BRECOVERYQ 12$11.12-6.11%
- NVAXBUYNovavax, Inc.$1.8BBULLQ 10$11.01+1.26%
- VALNSELLValneva SE$540MCRISISQ -1$5.69-6.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PCVX?
- LOPJLB’s latest quantitative signal on Vaxcyte, Inc. (PCVX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is PCVX in?
- Vaxcyte, Inc. (PCVX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Vaxcyte, Inc. (PCVX) do?
- Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasiv…